NasdaqGS:VTRSPharmaceuticals
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review
Viatris (VTRS) has drawn fresh attention after a busy February that combined its fourth quarter and full year 2025 results, new 2026 revenue guidance, an affirmed dividend policy, and progress on an eye-care drug filing.
See our latest analysis for Viatris.
The recent earnings update, new 2026 revenue guidance and FDA review of MR-141 appear to have reset expectations, with a 30 day share price return of 19.94% and a 1 year total shareholder return of 76.82% pointing to strong, building...